Thalassaemia and Iron Chelation: The Price of Regular Transfusion
A transfusion keeps a child with severe thalassaemia alive — but every bag of blood smuggles in iron the body has no way to throw out. Kept up month after month, that iron silently loads the heart until it fails. The story of thalassaemia treatment is really two battles: replacing the blood, then racing to clear the iron the blood leaves behind. Win only the first and the patient still dies — of the cure.
Layla is fifteen. Since infancy she has come to the day unit every three or four weeks for a red-cell transfusion — without it her beta-thalassaemia major would starve her tissues of oxygen and she would not have reached school age. The transfusions saved her. But this morning the cardiologist is frowning at an MRI: her heart muscle is soaked with iron. Not from her diet, not from tablets — from the very blood that kept her alive. Each unit she has ever received left its iron behind, and eight years of units have quietly filled her heart. Layla has beaten anaemia. Now she must beat the treatment for it.
What thalassaemia actually is
Adult haemoglobin is built from two kinds of globin chain, alpha and beta. In thalassaemia the body under-produces one of those chains — alpha-thalassaemia when the alpha chains fall short, beta-thalassaemia when the beta chains do. The chains that are still made pile up unpaired inside developing red cells, precipitate, and wreck them before they ever leave the marrow. This is ineffective erythropoiesis (Ineffective erythropoiesis): the marrow works furiously yet delivers few healthy cells, and the patient is anaemic. The severity is a spectrum — from a symptomless carrier (thalassaemia trait) to transfusion-dependent disease.
At the severe end sits beta-thalassaemia major: from the first months of life the child cannot make enough functioning haemoglobin to survive, and the only thing that keeps oxygen delivery adequate is regular, lifelong red-cell transfusion — typically every three to four weeks. Transfusion here is not a rescue for one bad day; it is the scaffolding of the whole life. And that is exactly where the second disease begins.
The trap: iron that cannot leave
Here is the cruel physiology. The human body has an efficient system for absorbing iron but NO regulated route to excrete it — no kidney or liver pathway that dumps surplus iron the way it clears most waste. In health that scarcely matters, because we absorb only what we lose. But each unit of transfused red cells carries roughly 200–250 mg of iron, and a transfusion-dependent patient receives dozens of units a year. The iron has nowhere to go. It accumulates. This is iron overload (Iron overload), and left unchelated it is what kills the well-transfused thalassaemic — not the anaemia, but its treatment.
Where does the iron settle, and why does it matter so much? The excess iron deposits in the organs richest in blood supply and metabolism. In the HEART it causes a cardiomyopathy and arrhythmias — cardiac iron overload is the leading cause of death in thalassaemia major. In the LIVER it drives fibrosis and eventually cirrhosis. In the ENDOCRINE glands it produces diabetes mellitus (pancreatic islet damage), hypogonadism (delayed or absent puberty, infertility), hypothyroidism, and short stature. A well-treated patient's whole prognosis turns on how well the iron is controlled.
Serum ferritin is the cheap, everyday gauge of iron load and we trend it, but it is imperfect — it also rises with infection and inflammation, and it does NOT reliably reflect the iron sitting in the heart. The modern standard is cardiac and hepatic MRI T2* (or R2*): a short T2* means heavy cardiac iron and a heart at risk, even when ferritin looks only 'moderately' raised. Treat the organ, not just the blood test.
The chelators: dragging iron back out
Since the body cannot excrete iron on its own, we give it a chemical partner that can. An iron chelator (Iron chelation is the process) is a molecule that binds free iron tightly and forms a complex the body CAN eliminate — in the urine, the stool, or both. Three chelators carry the modern regimen, and choosing between them is a real clinical decision balancing route, adherence, which organ's iron you most need to clear, and toxicity.
Desferrioxamine (Desferrioxamine, DFO) was the first effective agent and transformed survival. Its weakness is the route: it is not absorbed orally and must be given by SLOW subcutaneous or IV infusion over 8–12 hours, several nights a week, usually via a pump the patient wears overnight. It works — but asking a teenager to strap on an infusion pump five nights a week is a recipe for poor adherence, and non-adherence is the commonest reason iron creeps up. Side effects include retinal and auditory (ototoxicity — hearing loss) toxicity, and growth impairment in young children, so eye, hearing and growth monitoring are part of care.
Deferasirox (Deferasirox) changed the game because it is ORAL and taken just once a day, which dramatically improves adherence versus overnight infusions — the single biggest practical advance. The trade-off is monitoring: it can raise creatinine and impair renal function, disturb liver enzymes, and cause GI upset (nausea, diarrhoea) and rashes; rarely GI ulceration/bleeding. Renal and hepatic function are checked regularly. For many patients, swapping the nightly pump for a daily tablet is what finally brings the iron under control.
Deferiprone (Deferiprone) is also ORAL, and its standout property is that it is especially good at removing iron from the HEART — the very organ that most often kills — which is why it is often COMBINED with desferrioxamine in patients with heavy cardiac iron. Its defining danger is agranulocytosis (Agranulocytosis): a severe drop in neutrophils that leaves the patient open to life-threatening infection. This mandates regular (often weekly) neutrophil/blood-count monitoring, and stopping the drug at once if the count falls or the patient develops fever or sore throat.
- Thalassaemia = reduced production of alpha or beta globin → ineffective erythropoiesis and anaemia.
- Beta-thalassaemia major is transfusion-dependent — lifelong regular red-cell transfusion.
- The body cannot excrete iron; transfusions cause iron overload of heart, liver and endocrine glands.
- Cardiac iron (arrhythmia, cardiomyopathy) is the leading cause of death; monitor with T2* MRI, not ferritin alone.
- Desferrioxamine = infusion (poor adherence); deferasirox = oral once-daily; deferiprone = oral, best for cardiac iron but risks agranulocytosis.
Beyond chelation: modifying the disease
The classic strategy attacks the CONSEQUENCE — transfuse for the anaemia, then chelate the iron. Newer agents attack the anaemia itself. Luspatercept (Luspatercept) improves the maturation of red-cell precursors, easing the ineffective erythropoiesis so the marrow delivers more usable cells; in transfusion-dependent patients it can REDUCE the transfusion requirement, and less blood in means less iron in. It does not replace chelation, but by cutting the iron at its source it is a genuine addition to the toolbox. Allogeneic stem-cell transplantation remains the only established cure, and gene therapies are emerging.
Cross-link worth carrying: desferrioxamine is not only a chronic chelator — it is also the antidote in ACUTE iron poisoning (a child who swallows iron tablets), where it binds free iron and is excreted as ferrioxamine, turning the urine a characteristic 'vin rosé' colour. Same drug, same chemistry, opposite tempo. See the Iron chapter here for the acute-overdose story.
Everything in this story links outward to the rest of the syllabus. The source of the iron is the transfusion itself — how red cells are stored, matched and given belongs to the Blood products chapter. The end-organ damage lands squarely in endocrinology: the diabetes, hypogonadism and hypothyroidism of iron overload are managed exactly as in the Endocrine section, and a thalassaemic patient is often a shared cardiology, hepatology and endocrine case. Thalassaemia is a small disease that touches half the syllabus.
- Giving iron supplements to a thalassaemic patient. Their microcytic anaemia looks like iron deficiency but they are iron OVERLOADED — extra iron is harmful, even dangerous.
- Trusting a 'only moderately' raised ferritin and ignoring cardiac iron. Ferritin misses heart iron; order a T2* MRI before reassuring anyone.
- Prescribing deferiprone and skipping the blood counts. Miss the neutrophil monitoring and you miss agranulocytosis until the patient is septic.
- Treating adherence as the patient's problem alone. Nightly infusions fail because they are hard; switching to an oral chelator is often the real fix.
A 15-year-old with transfusion-dependent beta-thalassaemia major has heavy cardiac iron on T2* MRI. Which chelator is particularly valued for removing iron from the heart, but requires regular neutrophil-count monitoring for agranulocytosis?
- Thalassaemia under-produces alpha or beta globin; severe beta-major needs lifelong regular transfusion.
- The body cannot excrete iron, so transfusions overload the heart (top killer), liver and endocrine glands.
- Three chelators: desferrioxamine (infusion), deferasirox (oral daily, best adherence), deferiprone (oral, best for cardiac iron, risks agranulocytosis).
- Never give iron to a thalassaemic; monitor cardiac iron with T2* MRI, not ferritin alone; luspatercept can cut transfusion need.
- Hoffbrand AV, Moss PAH. Hoffbrand's Essential Haematology — Genetic disorders of haemoglobin: the thalassaemias and iron overload.
- Hoffbrand AV, Higgs DR, et al. Postgraduate Haematology — Thalassaemia syndromes and iron chelation therapy.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Iron chelating agents (desferrioxamine, deferasirox, deferiprone).
- Katzung BG. Basic & Clinical Pharmacology — Agents used in anaemias; iron overload and chelation.
- Cappellini MD, et al. Guidelines for the Management of Transfusion-Dependent Thalassaemia (TIF) — Transfusion, iron overload monitoring (T2* MRI) and chelation.
